March 14, 2008 - Eisai Co., Ltd. announced that the company submitted an application for a new oral jelly formulation of Aricept® (donepezil hydrochloride) in Japan. If approved, it will become the first Alzheimer's disease treatment available in an oral jelly formulation in the world.
Generally, Alzheimer's disease affects eldery population, and there are some patients who have difficulty swallowing a tablet or granule formulation with water due to the decline in their ability to swallow or the water enters into their trachea while taking the medication... Eisai's Press Release -
Blog Archive
-
▼
2008
(79)
-
▼
March
(11)
- ExonHit, EHT 0202 Counters Scopolamine's Detriment...
- Cryo-Cell International : Umbilical Cord Blood Cel...
- Evotec's EVT 101 : to Penetrate the Brain in Man a...
- Eisai, Application for Aricept Oral Jelly Formulat...
- Neurobiological Technologies and Buck Institute, t...
- Bar Harbor BioTechnology : New Line of StellARrays
- Power3 Medical , Three Hundred Patient Clinical Va...
- Pharmatrophix Alzheimer's Drug Discovery Foundatio...
- Hunter-Fleming and Newron, continuation of phase I...
- Debiopharm's Debio 9902 SR in Alzheimer’s disease,...
- Power3 Medical, Patent Application for Forty-Seven...
-
▼
March
(11)